Advertisement

Tripmiddelen: lsd en psychedelische paddenstoelen

  • Hylke Vervaeke

Psychedelische paddenstoelen worden al duizenden jaren gebruikt door de mensheid. In grotten op het Tassiliplateau in Algerije zijn spectaculaire rotstekeningen teruggevonden van minstens 5500 jaar oud. De bekendste beeldt een man uit met een bijenhoofd en paddenstoelen groeiend op het hele lichaam.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Referenties

  1. Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamide. Addiction 1993; 88(10): 1327–1334.PubMedCrossRefGoogle Scholar
  2. Abraham MD, Cohen PDA, Kaal HL. Licit and illicit drug use in the Netherlands, 2001. Amsterdam: Mets; 2002.Google Scholar
  3. Abraham HD, Aldridge AM, Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology 1996; 14(4): 285–298.PubMedCrossRefGoogle Scholar
  4. Bogers H, Snelders S, Plomp H. De psychedelische (r)evolutie. Amsterdam: Bres; 1993.Google Scholar
  5. Brown D. Psychedelic healing? Hallucinogenic drugs, which blew minds in the 1960s, soon may be used to treat mental ailments. Scientifi c American Mind 2007; Dec 2007/Jan 2008: 66–71.Google Scholar
  6. Buster M, Brussel G. van. Acute medische hulp in verband met incidenten door het gebruik van roesmiddelen in Amsterdam. Een stijgende trend van paddo-incidenten. Amsterdam: GGD; 2007.Google Scholar
  7. Calvino J. et al. Voluntary ingestion of Cortinarius mushrooms leading to chronic interstitial nephritis. Am J Nephrol 1998; 18(6): 565–569.PubMedCrossRefGoogle Scholar
  8. Carter OL. et al. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci 2005; 17(10): 1497–1508.PubMedCrossRefGoogle Scholar
  9. Colpaert FC. Discovering risperidone: the LSD model of psychopathology. Nat Rev Drug Discov 2003; 2(4): 315–320.PubMedCrossRefGoogle Scholar
  10. Coördinatiepunt Assessment en Monitoring nieuwe drugs (CAM). Risicoschatting van psilocine en psilocybine bevattende paddenstoelen (paddo's). Bilthoven; 2007.Google Scholar
  11. Dart R. Medical Toxicology. Lippincott: Williams & Wilkins; 2003.Google Scholar
  12. Drug Enforcement Administration (DEA). LSD in de United States. US Department of Justice; 1995.Google Scholar
  13. Dyck E. Flashback: psychiatric experimentation with LSD in historical perspective. Can J Psychiatry 2005; 50(7): 381–388.PubMedGoogle Scholar
  14. Espiard ML. et al. Hallucinogen persisting perception disorder after psilocybin consumption: a case study. Eur Psychiatry 2005; 20(5-6): 458–460.PubMedCrossRefGoogle Scholar
  15. Fantegrossi WE, Woods JH, Winger G. Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol 2004; 15(2): 149–157.PubMedCrossRefGoogle Scholar
  16. Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 2004; 99(6): 686.PubMedCrossRefGoogle Scholar
  17. Gonzalez-Maeso J. et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007; 53(3): 439–452.PubMedCrossRefGoogle Scholar
  18. Gouzoulis-Mayfrank E. et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebocontrolled study. Psychopharmacology (Berl) 1999; 142(1): 41–50.CrossRefGoogle Scholar
  19. Gresch PJ. et al. Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex. Neuropsychopharmacology 2005; 30(9): 1693–1702.PubMedCrossRefGoogle Scholar
  20. Griffiths RR. et al, Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 2006; 187(3): 268–83; discus 284–92.Google Scholar
  21. Griffiths RR. et al, Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 2008; in press.Google Scholar
  22. Grof S. The Effects of LSD on Chromosomes, Genetic Mutation, Fetal Development and Malignancy. In: LSD Psychotherapy. California: Hunter House Publishers; 1994.Google Scholar
  23. Halpern JH, Pope HG. Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend 1999; 53(3): 247–256.PubMedCrossRefGoogle Scholar
  24. Halpern JH, Pope HG. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 2003; 69(2): 109–119.PubMedCrossRefGoogle Scholar
  25. Hasler F. et al. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl) 2004; 172(2): 145–146.CrossRefGoogle Scholar
  26. Hasler F. et al. Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. J Pharm Biomed Anal 2002; 30(2): 331–339.PubMedCrossRefGoogle Scholar
  27. Hillebrand J, Olszewski D, Sedefov R. Hallucinogenic mushrooms: an emerging trend case study, Papers ET., Editor. European Monitoring Centre for Drugs and Drug Addiction: Lissabon; 2006.Google Scholar
  28. Hofmann A. LSD: my problem child. MAPS; 2005.Google Scholar
  29. Isbell H. et al. Tolerance to diethylamide of lysergic acid (LSD-25). Fed Proc 1955; 14: 354.Google Scholar
  30. Korf DJ, Benschop A, Rots G. Geweld, alcohol en drugs bij jeugdige gedetineerden en school drop-outs. Tijdschrift voor Criminologie 2005; 47: 239–254.Google Scholar
  31. Korf D, Nabben T, Benschop A. Antenne 2003. Trend in alcohol, tabak en drugs bij jonge Amsterdammers. Amsterdam: Rozenberg Publishers; 2004.Google Scholar
  32. Lerner AG. et al. Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features. Int Clin Psychopharmacol 2003; 18(2): 101–105.PubMedCrossRefGoogle Scholar
  33. Li Z. et al. Stability study of LSD under various storage conditions. J Anal Toxicol 1998; 22(6): 520–525.PubMedGoogle Scholar
  34. Meyer J, Quenzer L. Psychopharmacology. Drugs, the brain and behavior. Massachusetts: Sinauer Associates; 2005.Google Scholar
  35. Monshouwer K. et al. Jeugd en riskant gedrag: kerngegevens uit het peilstationsonderzoek 2003. Roken, drinken, drugsgebruik en gokken onder scholieren vanaf tien jaar. Utrecht: Trimbos Instituut; 2004.Google Scholar
  36. Moreno FA. et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006; 67(11): 1735–1740.PubMedCrossRefGoogle Scholar
  37. Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101(2): 131–181.PubMedCrossRefGoogle Scholar
  38. Ouwehand, AW. et al. Kerncijfers Verslavingszorg 2006. Houten: Landelijk Alcohol en Drugs Informatie Systeem (LADIS); 2007.Google Scholar
  39. Papac DI, Foltz RL. Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. J Anal Toxicol 1990; 14(3): 189–190.PubMedGoogle Scholar
  40. Passie T. et al. The pharmacology of psilocybin. Addict Biol 2002; 7(4): 357–364.PubMedCrossRefGoogle Scholar
  41. Rodenburg G. et al. Nationaal Prevalentie Onderzoek Middelengebruik 2005. Rotterdam: IVO; 2007.Google Scholar
  42. Schultes R, Hofmann A. Over de planten der Goden. Oorsprong van het gebruik van hallucinogenen. Utrecht: Het Spectrum; 1997.Google Scholar
  43. Sewell RA, Halpern JH, Pope HG. Response of cluster headache to psilocybin and LSD. Neurology 2006; 66(12): 1920–1922.PubMedCrossRefGoogle Scholar
  44. Snelders S, Kaplan C. LSD therapy in Dutch psychiatry: changing socio-political settings and medical sets. Med Hist 2002; 46(2): 221–240.PubMedGoogle Scholar
  45. Stafford P. Psychedelics Encyclopedia. Berkeley: Ronin Publishing; 1992.Google Scholar
  46. Stone A. et al. Who is becoming hallucinogen dependent soon after hallucinogen use starts? Drug and Alcohol Dependence 2007; 87: 153–163.PubMedCrossRefGoogle Scholar
  47. Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 2001; 56(5): 495–507PubMedCrossRefGoogle Scholar
  48. Vollenweider FX. et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998; 9(17): 3897–3902.PubMedCrossRefGoogle Scholar
  49. Went GF van. Mutagenicity testing of 3 hallucinogens: LSD, psilocybin and delta 9-THC, using the micronucleus test. Experientia 1978; 34(3): 324–325.PubMedCrossRefGoogle Scholar
  50. Wittmann M. et al. Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol 2007; 21(1): 50–64.PubMedCrossRefGoogle Scholar
  51. Wouters M, Korf DJ. Wiet wijs: cannabisgebruik bij leerlingen in opvangprojecten en speciaal voortgezet onderwijs. Amsterdam: Rozenberg Publishers; 2004.Google Scholar

Websites

  1. Multidisciplinary Association for Psychedelic Studies: www.maps.org.

Copyright information

© Bohn Stafleu van Loghum 2008

Authors and Affiliations

  • Hylke Vervaeke

There are no affiliations available

Personalised recommendations